Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the Generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Scope of the Report
Contains an executive summary and data on value, volume and segmentation
Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
Incorporates in-depth five forces competitive environment analysis and scorecards
Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).
Includes a five-year forecast of the industry
Highlights
The global generics market grew by 3.1% in 2008 to reach a value of $191.8 billion.
In 2013, the global generics market is forecast to have a value of $292 billion, an increase of 52.2% since 2008.
Sales of ethical drugs proved the most lucrative for the global generics market in 2008, generating 80.9% of the market’s overall revenue.
Americas leads the global generics market accounting for 59.7% of the market's revenue.
Why you should buy this report
Spot future trends and developments
Inform your business decisions
Add weight to presentations and marketing materials
Save time carrying out entry-level research
Market Definition
The generics market consists of all sales of generic drugs for human use at ex-manufacturer prices. Datamonitor defines a generic as an officially-approved copy of an original product whose patent has expired, marketed either as a brand or using the generic name.
This definition excludes multi-source copy products that make up much of markets such as India, Spain and Italy. Multi-source copies are drugs still under patent that are offered by manufacturers other than the patent holders.
(0 items)
